阿伐可泮治疗ANCA相关血管炎的真实世界安全性评估
本研究基于FDA不良事件报告系统,对阿伐可泮相关不良事件进行 disproportion 分析、时间至事件分析和亚组分析。共识别3150份报告、8个阳性SOC信号和92个阳性PT信号(含34个既往未识别PT),中位TTO为48天,整体呈早期失败型模式;年龄≥65岁患者累积发生率更高,肝胆事件在女性和老年患者中更突出。结论认为阿伐可泮真实世界安全性良好,但需按年龄和事件类型进行风险导向监测。
要点
- 阿伐可泮相关不良事件整体呈早期失败型时间模式,中位TTO为48天。
- 年龄≥65岁患者不良事件累积发生率更高,肝胆事件在女性和老年患者中更常见。
- 共检出8个阳性SOC信号和92个阳性PT信号,含34个既往未识别PT,无高临床优先级信号。
核心结论
- 阿伐可泮在真实世界AAV患者中显示良好安全性,但年龄增长伴随不良事件风险增加,肝胆事件在老年和女性患者中更频繁。
研究设计与样本
- 基于FDA不良事件报告系统的全面审查与分析,采用disproportionality分析评估SOC和PT层面信号,并进行TTO、WSP和累积发生率分析及性别和年龄亚组分析。
主要发现
- 共识别3150份阿伐可泮相关不良事件报告,检出8个阳性SOC信号和92个阳性PT信号,其中34个为既往未识别PT。
- 中位TTO为48天,整体WSP分析提示早期失败型模式,但事件特异性分析显示异质性时间模式。
- 年龄≥65岁患者不良事件累积发生率更高,肝胆事件为首要事件且在女性和老年(≥65岁)患者中占主导。
关键数值与推荐
- 无高临床优先级信号;中位TTO为48天;年龄≥65岁患者累积发生率更高。
临床怎么用
- 临床应基于年龄和事件类型制定风险导向和事件特异性监测策略,尤其关注老年和女性患者的肝胆事件。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Postmarketing safety data of avacopan, the first Food and Drug Administration (FDA) approved drug in a decade for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), are currently limited. This study aims to conduct a comprehensive real-world evaluation of its adverse events (AEs). METHODS: The FDA Adverse Event Reporting System was comprehensively reviewed and analysed. Disproportionality analysis was conducted to evaluate the significance of avacopan-related AEs at both system organ class (SOC) and preferred terms (PTs) levels. Time-to-onset (TTO), Weibull shape parameter (WSP) analysis and cumulative incidence analyses were performed to explore the temporal patterns of AE occurrence. Additionally, subgroup analyses based on gender and age were undertaken. RESULTS: A total of 3150 reports of avacopan-related AEs were identified. 8 positive SOC signals and 92 positive PT signals were detected, including 34 previously unrecognised PTs. None was classified as a high clinical priority. The median TTO was 48 days. Overall WSP analyses suggested an early failure type pattern, while event-specific analyses demonstrated heterogeneous temporal patterns. Patients aged≥65 years had a higher cumulative incidence of AEs. Hepatobiliary events were the leading ones, with a predominance of reports involving female and geriatric (≥65 years) patients. CONCLUSION: Avacopan demonstrated a favourable safety profile in patients with AAV in real-world settings. The overall AE risk increased with age, while hepatobiliary events were particularly more frequent among geriatric and female patients. Our study uncovered previously unrecognised AEs as well. These findings highlighted the need for risk-informed and AE-specific monitoring strategies to support individualised management.
引用
- Han XY, Li ZY, Chen SF, et al. Real-world safety assessment of avacopan in patients with antineutrophil cytoplasmic antibody-associated vasculitis. RMD Open. 2026. PMID: 41881505. doi:10.1136/rmdopen-2025-006439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。